Insider Trading Alert - HERO, AVNR And CNMD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Aug. 1, 2014, 63 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $28,592,784.28.

Highlighted Stocks Traded by Insiders:

Hercules Offshore (HERO) - FREE Research Report

Noe James William, who is Executive Vice President at Hercules Offshore, sold 75,000 shares at $3.58 on Aug. 1, 2014. Following this transaction, the Executive Vice President owned 259,339 shares meaning that the stake was reduced by 22.43% with the 75,000-share transaction.

The shares most recently traded at $3.32, down $0.26, or 7.72% since the insider transaction. Historical insider transactions for Hercules Offshore go as follows:

  • 4-Week # shares bought: 150,000
  • 4-Week # shares sold: 6,866
  • 12-Week # shares bought: 256,000
  • 12-Week # shares sold: 6,866
  • 24-Week # shares bought: 331,000
  • 24-Week # shares sold: 6,866

The average volume for Hercules Offshore has been 4.9 million shares per day over the past 30 days. Hercules Offshore has a market cap of $567.6 million and is part of the basic materials sector and energy industry. Shares are down 48.01% year-to-date as of the close of trading on Friday.

Hercules Offshore, Inc., together with its subsidiaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide. The company operates through Domestic Offshore, International Offshore, and International Liftboats segments. Currently, there are 5 analysts who rate Hercules Offshore a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HERO - FREE

TheStreet Quant Ratings rates Hercules Offshore as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full Hercules Offshore Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AVANIR Pharmaceuticals (AVNR) - FREE Research Report

Katkin Keith, who is President and CEO at AVANIR Pharmaceuticals, sold 9,670 shares at $5.26 on Aug. 1, 2014. Following this transaction, the President and CEO owned 760,412 shares meaning that the stake was reduced by 1.26% with the 9,670-share transaction.

The shares most recently traded at $5.35, up $0.09, or 1.68% since the insider transaction. Historical insider transactions for AVANIR Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 455,759
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 481,355
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 481,355

The average volume for AVANIR Pharmaceuticals has been 2.6 million shares per day over the past 30 days. AVANIR Pharmaceuticals has a market cap of $832.7 million and is part of the health care sector and drugs industry. Shares are up 56.85% year-to-date as of the close of trading on Friday.

Avanir Pharmaceuticals, Inc., together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. Currently, there are 2 analysts who rate AVANIR Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AVNR - FREE

TheStreet Quant Ratings rates AVANIR Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow. Get the full AVANIR Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Conmed (CNMD) - FREE Research Report

Hartman Curt R, who is Interim CEO at Conmed, bought 10,000 shares at $39.25 on Aug. 1, 2014. Following this transaction, the Interim CEO owned 11,000 shares meaning that the stake was boosted by 1000% with the 10,000-share transaction.

The shares most recently traded at $38.12, down $1.13, or 2.96% since the insider transaction. Historical insider transactions for Conmed go as follows:

  • 4-Week # shares sold: 1,600
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 1,600
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 1,600

The average volume for Conmed has been 246,400 shares per day over the past 30 days. Conmed has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 9.53% year-to-date as of the close of trading on Friday.

CONMED Corporation provides surgical devices and equipment for minimally invasive procedures and monitoring. The stock currently has a dividend yield of 2.05%. The company has a P/E ratio of 31.2. Currently, there are 2 analysts who rate Conmed a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNMD - FREE

TheStreet Quant Ratings rates Conmed as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Conmed Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins